13 September 2022 | BST (UTC+1)

Rhiannon David

Director Microphysiological Systems (MPS)
AstraZeneca
Rhiannon David
Dr Rhiannon David is Director of Microphysiological Systems (MPS) in Clinical Pharmacology and Safety Sciences at AstraZeneca, Cambridge, UK. Rhiannon leads the development and integration of advanced cell models, including spheroids and MPS, to improve the human-translation of pre-clinical safety assessment. Prior to joining AZ, following completion of her PhD at the Univeristy of Birmingham, Rhiannon undertook postdoctoral research at Imperial College London where she developed an interest in novel techniques that would improve the in vivo relevance of in vitro assays. After joining AZ in 2015, Rhiannon led the development of a bone marrow MPS for improved pre-clinical safety assessment. Rhiannon is now Director of MPS in Safety Innovation and leads the development and integration of advanced cell models, including spheroids and MPS, to improve the human-translation of pre-clinical safety assessment.

Sessions

No data was found

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.